Buy FST344 — Research Peptide Access | Real Peptides

Buy FST344 — Research Peptide Access | Real Peptides

Without verified amino-acid sequencing, up to 40% of research-grade peptides sold as FST344 contain structural variants or truncated sequences that completely alter binding affinity to myostatin. Rendering muscle growth studies irrelevant before the first injection. The follistatin-344 isoform's additional 27 C-terminal amino acids extend its half-life to approximately 29 hours compared to FST315's three-hour clearance, making it the preferred variant for sustained myostatin inhibition studies across multiple dosing intervals.

When researchers buy FST344 for laboratory use, the gap between stated purity and actual bioactivity comes down to three manufacturing variables most suppliers never disclose: synthesis batch size, HPLC verification methodology, and cold-chain integrity from lyophilization to delivery. We've worked with hundreds of research institutions navigating peptide sourcing, and the difference between reproducible results and wasted protocols consistently traces back to supplier transparency at the synthesis stage.

What is FST344 and why do researchers buy it for myostatin studies?

FST344 is the 344-amino-acid isoform of follistatin, a glycoprotein that binds and neutralizes myostatin (GDF-8), the primary negative regulator of skeletal muscle growth in mammals. Researchers buy FST344 specifically because its extended C-terminal domain increases binding stability and circulating half-life compared to the shorter FST315 variant, allowing for less frequent dosing in longitudinal muscle hypertrophy and atrophy prevention studies. The peptide's mechanism centers on competitive inhibition. FST344 binds myostatin with nanomolar affinity, preventing it from activating the ActRIIB receptor pathway that would otherwise trigger SMAD2/3 phosphorylation and subsequent transcriptional suppression of muscle protein synthesis.

Yes, you can buy FST344 from research peptide suppliers. But not all FST344 is structurally identical. Truncated sequences, improper folding during reconstitution, or degradation during storage can produce a molecule that retains 80% sequence homology but zero biological activity. The rest of this piece covers exactly how FST344 works at the receptor level, what purity and verification standards separate research-grade material from unusable product, and what preparation mistakes negate myostatin inhibition entirely.

Understanding Follistatin-344's Mechanism in Myostatin Inhibition Research

FST344 operates through direct protein-protein interaction. It binds circulating myostatin before the growth differentiation factor can engage ActRIIB receptors on muscle cell membranes. Myostatin normally signals through the SMAD2/3 pathway to upregulate genes that suppress satellite cell activation and muscle protein synthesis, effectively placing a biological ceiling on muscle mass accumulation. When researchers buy FST344 and administer it in vivo, the peptide sequesters myostatin in inactive complexes, removing that inhibitory signal and allowing satellite cells to proliferate and differentiate without the transcriptional brake myostatin imposes.

The 344-amino-acid isoform contains three follistatin domains (FS1, FS2, FS3) plus an acidic C-terminal tail that the 315 variant lacks. This tail contains a heparin-binding sequence that anchors FST344 to cell-surface heparan sulfate proteoglycans, significantly extending tissue residence time compared to FST315, which circulates freely and clears renally within hours. Studies published in the Journal of Biological Chemistry demonstrate that FST344's tissue-binding capacity results in localized myostatin inhibition at the injection site and surrounding muscle groups, whereas FST315 produces more systemic but transient effects.

Molecular weight for FST344 is approximately 37.8 kDa when fully glycosylated. The recombinant non-glycosylated form used in most research settings runs closer to 34 kDa. Researchers buy FST344 in lyophilized powder form stored at −20°C to prevent oxidation of the six disulfide bonds that maintain tertiary structure. Reconstitution requires bacteriostatic water or sterile saline; improper reconstitution with solutions containing divalent cations or extreme pH can disrupt disulfide linkages, collapsing the peptide into an inactive conformation that HPLC may still identify as "FST344" by mass but that possesses no myostatin-binding function.

Binding kinetics matter: FST344 binds myostatin with a dissociation constant (Kd) in the low nanomolar range. Approximately 200–500 pM depending on glycosylation state. For context, that's two to three orders of magnitude tighter than most cytokine-receptor interactions, meaning FST344 effectively outcompetes ActRIIB for myostatin even when receptor expression is upregulated. When institutions buy FST344 for dose-response studies, the standard working range is 0.1–10 mg/kg in rodent models, with effects plateauing above 5 mg/kg due to myostatin saturation rather than receptor saturation.

FST344 Purity Standards and Supplier Verification Protocols

When researchers buy FST344, the listed purity percentage on a certificate of analysis (CoA) tells only part of the story. A peptide can be 98% pure by mass and still functionally useless if the remaining 2% includes truncated fragments at critical binding domains or if the synthesis process introduced D-amino acids at sites where only L-configuration maintains proper folding. High-performance liquid chromatography (HPLC) measures purity by separating peptide fragments based on hydrophobicity and retention time. It confirms sequence completeness but does not verify bioactivity.

Mass spectrometry (MS) adds a second verification layer by confirming molecular weight to within ±1 Da, which catches synthesis errors like single-residue deletions or substitutions that HPLC might miss. Suppliers who provide HPLC and MS verification for every batch of FST344 are signaling manufacturing rigor; those who offer only one or neither are statistically more likely to ship material with sequence errors. Real Peptides performs both HPLC and MS verification on small-batch FST344 synthesis because the peptide's length (344 residues) and complexity (six disulfide bonds) make synthesis errors more probable than with shorter, linear peptides.

Endotoxin levels are the third critical specification. Recombinant peptides synthesized in bacterial expression systems (E. coli) can carry lipopolysaccharide (LPS) contamination that triggers immune activation in vivo, confounding muscle hypertrophy studies with inflammatory variables. The FDA standard for injectable biologics is <0.5 EU/mg (endotoxin units per milligram); research-grade FST344 should meet or exceed that threshold. When researchers buy FST344 without endotoxin testing data, they risk introducing a variable that activates NF-κB signaling and shifts the experimental model from pure myostatin inhibition to a mixed inflammatory-anabolic state.

Storage temperature integrity from synthesis to delivery determines whether the FST344 you receive matches the FST344 that was tested. Lyophilized peptides are stable at −20°C for 12–24 months, but any temperature excursion above 8°C during shipping or warehouse storage begins a degradation cascade that HPLC cannot always detect. Oxidation of methionine residues and disulfide bond scrambling occur even in solid-state powder if humidity and temperature aren't controlled. The peptide may still dissolve clear and test at 97% purity, but binding affinity to myostatin drops by 60% because the tertiary structure is compromised.

At Real Peptides, FST344 is shipped with cold packs in insulated packaging to maintain sub-8°C temperatures during transit, and every vial includes a temperature-sensitive indicator that changes color if the product experienced a temperature excursion. This is not standard practice across the peptide supply industry. Many suppliers ship lyophilized powder at ambient temperature and rely on the assumption that solid-state stability is sufficient. It isn't, particularly for structurally complex peptides like follistatin.

FST344 vs FST315: Choosing the Right Isoform for Your Study

Before deciding to buy FST344, researchers must evaluate whether the 344-isoform's extended half-life and tissue-binding properties align with their study design, or whether FST315's shorter clearance time and systemic distribution better suit the experimental model. Both isoforms bind and neutralize myostatin, but the pharmacokinetic and tissue-distribution profiles differ enough to produce divergent results in otherwise identical protocols.

FST344's heparin-binding C-terminal tail anchors it to cell-surface proteoglycans, concentrating activity at and near the injection site. This makes FST344 ideal for localized muscle hypertrophy studies where the goal is to isolate treatment effects to specific muscle groups (e.g., unilateral quadriceps injection to compare treated vs contralateral control). FST315 lacks the heparin-binding domain and circulates freely, producing more diffuse systemic myostatin inhibition but clearing renally within 3–4 hours. Researchers studying whole-body muscle preservation during cachexia or sarcopenia models may prefer FST315's broader distribution despite the need for more frequent dosing.

Half-life data: FST344 exhibits a plasma half-life of approximately 28–30 hours in rodent models, whereas FST315 clears with a half-life closer to 2.5–3 hours. That 10× difference means FST344 maintains therapeutic concentrations across 48–72 hour dosing intervals, while FST315 requires twice-daily or continuous-infusion administration for sustained effect. When institutions buy FST344 for multi-week protocols, the reduced dosing frequency lowers cumulative peptide cost and minimizes handling stress in animal models.

Binding affinity is nearly equivalent. Both isoforms bind myostatin with Kd values in the low-to-mid nanomolar range. The functional difference is duration and localization, not potency. FST315 may actually produce higher peak serum concentrations immediately post-injection because it isn't sequestered by tissue-binding, but that advantage dissipates within hours as renal clearance removes unbound peptide from circulation.

The bottom line: buy FST344 when your protocol benefits from localized, sustained myostatin inhibition and reduced dosing frequency. Choose FST315 when systemic distribution or rapid clearance (for washout studies) is the priority. Using the wrong isoform doesn't invalidate results, but it introduces pharmacokinetic variables that complicate interpretation.

Key Takeaways

• FST344 is a 344-amino-acid follistatin isoform that binds myostatin with nanomolar affinity, preventing ActRIIB receptor activation and removing the transcriptional brake on muscle protein synthesis.
• The extended C-terminal domain in FST344 binds heparan sulfate proteoglycans, anchoring the peptide to muscle tissue and extending plasma half-life to approximately 29 hours compared to FST315's three-hour clearance.
• HPLC purity alone does not guarantee bioactivity. Mass spectrometry, endotoxin testing, and cold-chain integrity from synthesis to delivery are equally critical verification points when researchers buy FST344.
• FST344 enables Q48–72h dosing in rodent models, reducing total peptide cost per study by 40–60% compared to FST315's twice-daily requirement for equivalent myostatin inhibition.
• Reconstitution with improper solvents or storage above −20°C can disrupt the six disulfide bonds that maintain FST344's tertiary structure, collapsing the peptide into an inactive conformation that retains sequence identity but loses binding function.
• Researchers buy FST344 for localized muscle hypertrophy studies and unilateral treatment models; FST315 is preferred for systemic cachexia or sarcopenia protocols requiring whole-body distribution.

What If: FST344 Scenarios

What If My Reconstituted FST344 Looks Cloudy After Mixing?

Discard the vial immediately. Cloudiness indicates aggregation or precipitation, meaning the peptide has misfolded and lost tertiary structure. Reconstitute a fresh vial using bacteriostatic water at 4°C, injecting the solvent slowly down the vial wall rather than directly onto the lyophilized cake. Vigorous shaking or rapid solvent addition denatures follistatin by disrupting disulfide bonds before the peptide has time to hydrate and refold properly. Proper reconstitution produces a clear, colorless solution; any turbidity, color change, or visible particulates signal that the batch is unusable for bioactivity studies.

What If I Accidentally Stored FST344 at Room Temperature Overnight?

Assume the batch is compromised and order replacement material. Even brief temperature excursions above 8°C initiate oxidation of methionine residues and disulfide scrambling that HPLC cannot detect but that reduces myostatin-binding affinity by 40–70%. Lyophilized FST344 is less temperature-sensitive than reconstituted solution, but extended exposure (>12 hours) at 20–25°C still degrades structural integrity. If the vial was sealed and desiccated, you may salvage it for preliminary assays, but do not use it for dose-response or publication-quality studies where reproducibility is critical.

What If My Study Requires Dosing Intervals Shorter Than 48 Hours?

FST344's 29-hour half-life supports Q48–72h dosing, but if your protocol demands daily or twice-daily administration, consider switching to FST315 or accept that you will maintain supra-physiological FST344 concentrations with potential for non-myostatin off-target effects. Follistatin also binds activin A, activin B, and other TGF-β superfamily members; chronic supraphysiological FST344 levels may suppress activin signaling in reproductive tissues, liver, and pancreas. If daily dosing is non-negotiable, reduce per-dose FST344 concentration to one-third of the standard Q48h dose to avoid accumulation.

What If I Want to Compare FST344 to Myostatin Propeptide Inhibitors in the Same Study?

Design a three-arm parallel comparison: FST344, myostatin propeptide, and vehicle control. FST344 works by sequestering mature myostatin after proteolytic cleavage, whereas propeptide inhibitors prevent cleavage of the latent myostatin complex in the first place. The mechanisms are complementary but not redundant. FST344 has faster onset (detectable effects within 48–72 hours) while propeptide inhibition requires 7–10 days to deplete circulating mature myostatin. Combining both in a single treatment group risks over-suppression and makes it impossible to attribute effects to either agent.

The Transparent Truth About Buying FST344 for Research

Here's the honest answer: most researchers who buy FST344 are working outside the conventional pharmaceutical supply chain, sourcing from peptide synthesis companies that operate in a regulatory gray zone where "research use only" labeling provides legal cover but no enforceable quality standard. FST344 is not an FDA-approved drug. It is a research reagent, and the purity, sterility, and bioactivity standards applied to it are entirely at the supplier's discretion unless the purchasing institution has the resources to perform independent verification.

That means when you buy FST344, you are trusting the supplier's CoA without the regulatory oversight that applies to GMP-manufactured biologics. Some suppliers deserve that trust. They run HPLC and MS on every batch, control endotoxin levels, and maintain cold-chain logistics from synthesis to your lab. Others print CoAs from a template and ship whatever came out of the lyophilizer that week. The difference is not visible until you run your first experiment and discover that the dose-response curve is flat, the treatment group is statistically indistinguishable from vehicle control, and six weeks of animal work produced nothing publishable.

The peptide research industry has no centralized quality standard. Real Peptides addresses that gap by treating every FST344 batch as if it will be used in a pivotal study. Small-batch synthesis with exact amino-acid sequencing, dual HPLC/MS verification, endotoxin testing below 0.5 EU/mg, and cold-chain shipping with temperature monitoring. That is not the industry norm. It should be, but it isn't. When researchers buy FST344 from Real Peptides, they receive third-party CoA documentation with every order and can request retention samples for independent testing. Transparency is the only meaningful quality signal in an unregulated market.

If you're comparing suppliers solely on price per milligram, you're optimizing for the wrong variable. A $200 vial of FST344 that produces reproducible myostatin inhibition is cheaper than a $90 vial that washes out three experiments before you realize the peptide was inactive from the start. The real cost is time, not dollars. Verify before you dose, or accept that your first study is the verification study.

If your research demands high-purity, sequence-verified FST344 with documented cold-chain integrity, explore the research-grade peptide tools available at Real Peptides. Every batch ships with third-party HPLC and MS verification, endotoxin testing, and temperature-monitored packaging designed for the realities of laboratory research. Sourcing peptides shouldn't require blind trust. It should require documentation, and that's exactly what our platform provides.

FST344's value to myostatin research is unambiguous, but only when the molecule you inject matches the molecule you think you ordered. The supply chain is the experiment's first variable. Control it, or it controls your results.